120 related articles for article (PubMed ID: 23615728)
21. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
22. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
[TBL] [Abstract][Full Text] [Related]
23. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
[TBL] [Abstract][Full Text] [Related]
24. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
25. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.
Yang Y; Wu N; Shen J; Teixido C; Sun X; Lin Z; Qian X; Zou Z; Guan W; Yu L; Rosell R; Liu B; Wei J
Gastric Cancer; 2016 Jul; 19(3):778-88. PubMed ID: 26404902
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.
Yan HH; Jung KH; Son MK; Fang Z; Kim SJ; Ryu YL; Kim J; Kim MH; Hong SS
Oncotarget; 2014 Oct; 5(19):9150-68. PubMed ID: 25193856
[TBL] [Abstract][Full Text] [Related]
27. Predictive role of computer simulation in assessing signaling pathways of crizotinib-treated A549 lung cancer cells.
Xia P; Mou FF; Wang LW
Asian Pac J Cancer Prev; 2012; 13(7):3119-21. PubMed ID: 22994720
[TBL] [Abstract][Full Text] [Related]
28. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
Tachihara M; Kobayashi K; Ishikawa Y; Hori S; Tamura D; Otera H; Funada Y; Nishimura Y
Jpn J Clin Oncol; 2014 Aug; 44(8):762-4. PubMed ID: 24872405
[TBL] [Abstract][Full Text] [Related]
29. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
[No Abstract] [Full Text] [Related]
30. ATM/ATR and SMAD3 pathways contribute to 3-indole-induced G₁ arrest in cancer cells and xenograft models.
Huang SM; Lu KT; Wang YC
Anticancer Res; 2011 Jan; 31(1):203-8. PubMed ID: 21273599
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
32. CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway.
Tang MR; Wang YX; Guo S; Han SY; Wang D
Apoptosis; 2012 Sep; 17(9):927-37. PubMed ID: 22538441
[TBL] [Abstract][Full Text] [Related]
33. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
35. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
36. Effect of PF-02341066 and radiation on non-small cell lung cancer cells.
Tumati V; Kumar S; Yu L; Chen B; Choy H; Saha D
Oncol Rep; 2013 Mar; 29(3):1094-100. PubMed ID: 23254764
[TBL] [Abstract][Full Text] [Related]
37. Ocimum sanctum induces apoptosis in A549 lung cancer cells and suppresses the in vivo growth of Lewis lung carcinoma cells.
Magesh V; Lee JC; Ahn KS; Lee HJ; Lee HJ; Lee EO; Shim BS; Jung HJ; Kim JS; Kim DK; Choi SH; Ahn KS; Kim SH
Phytother Res; 2009 Oct; 23(10):1385-91. PubMed ID: 19277950
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
39. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1.
Dai X; Guo G; Zou P; Cui R; Chen W; Chen X; Yin C; He W; Vinothkumar R; Yang F; Zhang X; Liang G
J Exp Clin Cancer Res; 2017 Sep; 36(1):120. PubMed ID: 28882182
[TBL] [Abstract][Full Text] [Related]
40. Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors.
Wu H; Zeng C; Ye Y; Liu J; Mu Z; Xie Y; Chen B; Nong Q; Wu D
Mol Pharm; 2018 May; 15(5):1892-1900. PubMed ID: 29595984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]